secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001437749-22-026895
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Isoray Q1 FY2023 revenue down 33% to $1.72M; net loss widens to $4.07M
----------------------------------------------------------------------

- Revenue $1.72M vs $2.56M YoY; core prostate brachytherapy revenue fell 41%.
- Net loss $4.07M ($0.03 per share) vs $2.24M ($0.02) in prior year.
- Gross margin dropped to 24.1% from 40.1%; isotope supply disruption cited.
- Cash and equivalents $54.1M with no long-term debt; stockholders' equity $57.7M.
- Pending merger with Viewpoint Molecular Targeting noted; G&A rose 69% on deal costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/0001437749-22-026895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/isr20221109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer